^^^M^^^^fc
m
m.
THE CHEMISTRY IS SIMPLE WHEN YOU'RE STANDING ON THE RIGHT PLATFORM
Impossible drugs are now possible
A
•ccess a world of new opportunities in carbohydrate-based
drug discovery and glycochemistry with Synthon Chiragenics.
Our proprietary technology enables the synthesis of new drug candidates with multiple contiguous chiral centers (MC3) as well as molecular scaffolds based on structural and functional similarity to DNA. These structures provide the master key to therapeutically important compound classes that have been previously unavailable or impractical. Contact Synthon Chiragenics today to find out how our:
I
K
• Nucleoside/nucleotide analog chemistry can expedite
X
drug discovery based on enzyme inhibition in autoimmune diseases, diabetes and cancer. • Novel oxazolidinone synthesis program can be used in your development of antimicrobial therapies for the treatment of serious hospital infections.
E f l Synthon Chiragenics ™
C
O
R
P
O
R
A
T
I
O
N
New Chiral Chemistry...Naturally 7 Deer Park Drive • Monmouth Junction, NJ 08852 Tel (732) 274-0037 • Fax (732) 274-0502
[email protected] • www.synthoncorp.com
©2001 SYNTHHrCHn!
TCS4
Please visit us at: CPhl—London, October 8-10, Booth P54
